Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in May

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced that Jason Gardner, D.Phil., President and Chief Executive Officer, will participate in fireside chats at the following investor conferences this month:

• Cowen 2nd Annual Virtual Oncology Innovation Summit on Thursday, May 20, at 10:40 a.m. ET
• Oppenheimer Rare & Orphan Disease Summit on Friday, May 21, at 2:55 p.m. ET

Live webcasts of the fireside chats can be accessed on the Magenta Therapeutics website at https://investor.magentatx.com/events-and-presentations. The webcast replays will be available for 90 days following each event.

About Magenta Therapeutics

Magenta Therapeutics is a clinical-stage biotechnology company developing medicines to bring the curative power of stem cell transplant to more patients with blood cancers, genetic diseases and autoimmune diseases. Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise, a unique business model and broad networks in the stem cell transplant community to revolutionize immune reset for more patients.

Magenta is based in Cambridge, Mass. For more information, please visit www.magentatx.com.

Follow Magenta on Twitter: @magentatx.

Contacts

Magenta Therapeutics

Jim Haney, Senior Director, Investor Relations

317-909-4199

[email protected]

Lyndsey Scull, Director, Corporate Communications

202-213-7086

[email protected]

Jill Bertotti, Real Chemistry

714-225-6726

[email protected]